Iodine123labeled

Iodine-123 labeled compounds are radioactive substances used in nuclear medicine for diagnostic imaging and research. Iodine-123 is a metastable nuclear isomer of iodine-123, which decays by electron capture to stable xenon-123 with a half-life of approximately 13.22 hours.

Labeling compounds with iodine-123 involves replacing a non-radioactive iodine atom with radioactive iodine-123. This process is used to attach iodine-123 to biologically active molecules, such as proteins, peptides, or other small molecules. The resulting compounds can then be used to study various physiological processes, including iodine metabolism, thyroid function, and cancer biology.

Iodine-123 labeled compounds have several advantages over other radioactive isotopes, including a relatively long half-life, which allows for easier handling and storage. Additionally, iodine-123 emits low-energy gamma rays, which reduces the risk of radiation exposure to both patients and medical personnel.

Examples of iodine-123 labeled compounds include iodine-123 metaiodobenzylguanidine (I-123 mIBG), which is used to image neuroendocrine tumors, and iodine-123 iodoamino acids, which are used to study the kidney function in patients with kidney disorders.

Overall, iodine-123 labeled compounds have become an essential tool in nuclear medicine and research, providing valuable information on various physiological processes and disease states. However, the use of radioactive materials requires adherence to strict safety and handling protocols to minimize radiation exposure and ensure patient safety.